Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801592 | 0.89 | TDP1 (0.40) | KDM4EAKR1B1ALDH1A1TSHRRAB9A | |
| SCHEMBL6796488 | 0.75 | PGR (0.32) | MAPT | |
| SCHEMBL17567325 | 0.71 | KDM4E (0.50) | KDM4EAKR1B1MAPTNPC1RAB9A | |
| SCHEMBL7153475 | 0.71 | KDM4E (0.50) | KDM4EMAPTALDH1A1TSHRNPC1 | |
| SCHEMBL9838859 | 0.69 | KDM4E (0.42) | KDM4EAKR1B1POLBAPEX1RECQL | |
| SCHEMBL7151297 | 0.68 | KDM4E (0.44) | KDM4EAKR1B1MAPTALDH1A1TSHR | |
| SCHEMBL7171872 | 0.68 | KDM4E (0.50) | KDM4EAKR1B1POLBAPEX1RECQL | |
| SCHEMBL6802227 | 0.67 | KDM4E (0.43) | KDM4EAKR1B1POLBAPEX1RECQL | |
| SCHEMBL7818102 | 0.67 | KDM4E (0.40) | KDM4EAKR1B1POLBAPEX1RECQL | |
| SCHEMBL31085181 | 0.66 | KDM4E (0.49) | KDM4EAKR1B1MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | KDM4E 2246/4885AKR1B1 1407/4885POLB 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.